| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Flynn James E | 10% | $2,178,182 | 15,558,445 | Deerfield Management Company, L.P. | 27 Feb 2025 | |||
| Cystic Fibrosis Foundation | 10% | -50% | $349,175 | -$887,608 | 2,494,110 | -39% | Cystic Fibrosis Foundation | 27 Feb 2025 |
| OrbiMed Israel BioFund GP Limited Partnership | 1% | 276,150 | ORBIMED ISRAEL GP LTD. | 18 Jun 2025 |
As of 30 Sep 2025, 2 institutional investors reported holding 97,025 shares of BiomX Inc. - Common stock, par value $0.0001 per share (PHGE). This represents 0.35% of the company’s total 27,615,000 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 0 | $0 | -$83 | 0 | |
| 2025 Q3 | 97,025 | $50,938 | $0.52 | 2 | |
| 2025 Q2 | 97,025 | $42,693 | $0.45 | 2 | |
| 2025 Q1 | 97,025 | $53,916 | +$88 | $0.55 | 2 |
| 2024 Q4 | 96,866 | $70,722 | -$180,485 | $0.73 | 1 |
| 2024 Q3 | 300,942 | $306,960 | -$9,565,291 | $1.02 | 2 |
| 2024 Q2 | 23,249,529 | $7,814,136 | +$3,181,319 | $0.34 | 10 |
| 2024 Q1 | 13,770,839 | $6,196,607 | +$2,595,251 | $0.45 | 9 |
| 2023 Q4 | 8,090,280 | $2,264,622 | -$123,934 | $0.28 | 13 |
| 2023 Q3 | 7,452,452 | $2,623,356 | -$89,858 | $0.35 | 10 |
| 2023 Q2 | 7,707,696 | $2,773,941 | +$508,054 | $0.36 | 9 |
| 2023 Q1 | 6,330,423 | $1,930,752 | +$60,640 | $0.30 | 12 |
| 2022 Q4 | 6,162,512 | $1,150,412 | -$38,941 | $0.19 | 13 |
| 2022 Q3 | 6,160,749 | $2,095,000 | -$5,123 | $0.34 | 14 |
| 2022 Q2 | 6,178,650 | $4,511,000 | -$860,141 | $0.73 | 10 |
| 2022 Q1 | 6,615,338 | $12,767,000 | +$118,120 | $1.93 | 12 |
| 2021 Q4 | 6,557,269 | $10,492,000 | -$754,297 | $1.60 | 12 |
| 2021 Q3 | 6,951,985 | $21,271,508 | +$2,591,956 | $3.06 | 17 |
| 2021 Q2 | 6,092,788 | $33,266,828 | -$586,998 | $5.46 | 13 |
| 2021 Q1 | 6,181,431 | $44,013,000 | -$199,957 | $7.12 | 13 |
| 2020 Q4 | 6,275,013 | $40,034,000 | +$240,907 | $6.38 | 9 |
| 2020 Q3 | 6,223,539 | $39,457,000 | +$654,975 | $6.34 | 9 |
| 2020 Q2 | 6,122,733 | $33,795,000 | +$408,937 | $5.52 | 12 |
| 2020 Q1 | 6,035,721 | $42,249,000 | +$6,038,699 | $7.00 | 10 |
| 2019 Q4 | 5,158,604 | $49,961,000 | +$28,283,000 | $9.68 | 7 |
| 2019 Q3 | 100,141 | $1,016,000 | +$1,016,000 | $10.15 | 1 |